Arcutis to Report Third Quarter Financial Results
Arcutis Biotherapeutics (Nasdaq: ARQT) announced a conference call and webcast on November 8, 2022, at 5:00 p.m. ET to discuss its Q3 2022 financial results. The press release will be available after U.S. market close on the same day. Arcutis specializes in developing innovative therapies for immune-mediated dermatological diseases, utilizing a robust development platform with multiple clinical programs targeting conditions like scalp psoriasis and atopic dermatitis. For more details, visit www.arcutis.com.
- None.
- None.
WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 5:00 p.m. ET on Tuesday, November 8, 2022, to report its third quarter financial results.
The schedule for the press release and conference call/webcast is as follows:
- Q3 2022 Press Release: Tuesday, November 8, 2022, after the close of the U.S. financial markets
- Q3 2022 Earnings Call: Tuesday, November 8, 2022, at 5:00 p.m. ET
A live webcast of the call and the presentation material will be available on the “Events” section of the Company’s investor website. An archived replay of the webcast will be available on the Arcutis investor website following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp psoriasis, atopic dermatitis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and Twitter.
Forward-Looking Statements
This press release contains "forward-looking" statements. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, as amended on March 3, 2022, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
asheldon@arcutis.com
Investors
Eric McIntyre, Head of Investor Relations
emcintyre@arcutis.com
FAQ
When will Arcutis report its Q3 2022 financial results?
What time is the Arcutis Q3 2022 earnings call?
Where can I find the Arcutis Q3 2022 earnings call webcast?
What does Arcutis Biotherapeutics focus on?
